Eupraxia Pharmaceuticals
EPRXEupraxia Pharmaceuticals Inc. (TSX: EPRX) is a clinical-stage biotechnology company based in Canada. The company's primary business focus is the development of novel, locally delivered drug-device combination products. Its lead candidate, EP-104, is an investigational product designed to provide long-term, controlled release of a corticosteroid directly to a specific joint for the treatment of osteoarthritis pain. The company's therapeutic focus is on addressing conditions involving pain and inflammation. Its platform technology aims to concentrate therapeutic agents at the site of disease while intending to minimize systemic exposure and related side effects. Eupraxia is publicly traded on the Toronto Stock Exchange under the ticker symbol EPRX. Eupraxia's clinical development pipeline is centered on EP-104, which has completed a Phase 2 trial in knee osteoarthritis. The company is advancing this candidate into further clinical studies. The drug-device combination approach represents the core of its strategy to develop differentiated treatments within its target therapeutic areas.
EPRX · Stock Price
Historical price data
About
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) is a clinical-stage biotechnology company based in Canada. The company's primary business focus is the development of novel, locally delivered drug-device combination products. Its lead candidate, EP-104, is an investigational product designed to provide long-term, controlled release of a corticosteroid directly to a specific joint for the treatment of osteoarthritis pain. The company's therapeutic focus is on addressing conditions involving pain and inflammation. Its platform technology aims to concentrate therapeutic agents at the site of disease while intending to minimize systemic exposure and related side effects. Eupraxia is publicly traded on the Toronto Stock Exchange under the ticker symbol EPRX. Eupraxia's clinical development pipeline is centered on EP-104, which has completed a Phase 2 trial in knee osteoarthritis. The company is advancing this candidate into further clinical studies. The drug-device combination approach represents the core of its strategy to develop differentiated treatments within its target therapeutic areas.